Mira Pharmaceuticals Completes Acquisition, Reports Key Agreements
Ticker: MIRA · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5 million, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, material-agreement, equity-sale
TL;DR
Mira Pharma just closed an acquisition and signed new deals. Big moves happening!
AI Summary
Mira Pharmaceuticals, Inc. announced on September 29, 2025, the completion of an acquisition. The company also reported on the entry into a material definitive agreement and unregistered sales of equity securities. The filing details events related to the company's operations and financial activities.
Why It Matters
This 8-K filing indicates significant corporate activity for Mira Pharmaceuticals, including a completed acquisition and new agreements, which could impact its future growth and market position.
Risk Assessment
Risk Level: medium — The filing details a completed acquisition and unregistered sales of equity, which can introduce both opportunities and risks related to integration and dilution.
Key Players & Entities
- MIRA PHARMACEUTICALS, INC. (company) — Registrant
- Mira1a Therapeutics, Inc. (company) — Former Company Name
- September 29, 2025 (date) — Date of Report
- Florida (location) — State of Incorporation
- 001-41765 (identifier) — SEC File Number
FAQ
What was the nature of the material definitive agreement entered into by Mira Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What assets were acquired or disposed of by Mira Pharmaceuticals?
The filing states the completion of an acquisition or disposition of assets, but the specific assets involved are not detailed in the provided text.
When did Mira Pharmaceuticals change its name from Mira1a Therapeutics, Inc.?
Mira Pharmaceuticals, Inc. changed its name from Mira1a Therapeutics, Inc. on January 12, 2022.
What is Mira Pharmaceuticals' principal executive office address?
Mira Pharmaceuticals' principal executive offices are located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
What is the SIC code for Mira Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Mira Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-09-30 07:00:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
- $5 million — condition to closing, SKNY contributed $5 million in marketable securities to the Company
- $2,500,000 — (the "Rule"), which requires a minimum $2,500,000 stockholders' equity. On May 7, 2025, t
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 339KB
- 0001493152-25-016168.txt ( ) — 623KB
- mira-20250929.xsd (EX-101.SCH) — 3KB
- mira-20250929_lab.xml (EX-101.LAB) — 33KB
- mira-20250929_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: September 30, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer